Q1/2024 2/29/2024 EPS -0.760 ZacksConsensus -0.800 ActVsEst 0.040 - Beat
Nurix Therapeutics, Inc. - Common stock (NRIX)
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
NRIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRIX alerts
High impacting Nurix Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
NRIX
News
- Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions [Yahoo! Finance]Yahoo! Finance
- Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory ConditionsGlobeNewswire
- Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target lowered by analysts at Wells Fargo & Company from $32.00 to $25.00. They now have an "overweight" rating on the stock.MarketBeat
- Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target lowered by analysts at Stifel Nicolaus from $36.00 to $35.00. They now have a "buy" rating on the stock.MarketBeat
NRIX
Earnings
- 4/8/25 - Beat
NRIX
Sec Filings
- 4/8/25 - Form 10-Q
- 4/8/25 - Form 8-K
- 3/28/25 - Form DEFA14A
- NRIX's page on the SEC website